ATLANTA, GA USA (UroToday) - Abiraterone acetate is indicated for treatment of metastatic castration-resistant prostate cancer in men who have already received chemotherapy with docetaxel (Taxotere).
An androgen suppressant, abiraterone decreases production of testosterone by inhibiting a protein called CYP17A1.
The new oral drug will be marketed as Zytiga® by Johnson & Johnson’s Centocor Ortho Biotech of Horsham, Pa. It is to be used daily in combination with the steroid prednisone in late-stage disease.
The FDA considered abiraterone under its priority review program and acted ahead of its June 20, 2010, regulatory goal date. Approval was widely anticipated, as the abiraterone-prednisone combination was shown to prolong life by about 4 months in a randomized, international, phase III trial that enrolled 1,195 men whose disease was progressing after one or two chemotherapy regimens, including one with docetaxel.
In this exclusive podcast, Dr. Judd Moul discusses how to optimally sequence the use of Zytiga (abiraterone acetate) and when to determine its discontinuation of use.
Presented by Judd W. Moul, MD, FACS* at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA
*Director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University, Durham, NC USA
Judd Moul received his MD from Jefferson Medical College of Thomas Jefferson University (Pennsylvania) in 1982. He completed residencies in surgery (1982-1983) and urology (1983-1987) at Walter Reed Army Medical Center (Washington, DC). From there he completed a fellowship in urologic oncology at Duke University Medical Center (1988-1989). He is a fellow of the American College of Surgeons.
Dr. Moul's clinical interests include minimally invasive nerve-sparing radical prostatectomy, treatment of PSA-only or biochemical recurrence of prostate cancer, prostate cancer in African Americans, multidisciplinary management of prostate cancer, clinical trials in prostate disease, early-stage testicular cancer, prostate cancer and outcomes/database research.
Read highlights of an exclusive interview with Dr. Moul
View slides relating to Dr. Moul's presentation
